Pharmacotherapeutic strategies for the treatment of attention-deficit hyperactivity (ADHD) disorder with comorbid substance-use disorder (SUD)

References

• Moffitt TE, Houts R, Asherson P, et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry. 2015 Oct;172(10):967–977. PubMed PMID: 25998281; PubMed Central PMCID: PMCPMC4591104.
   PubMed Web of Science ®Google Scholar
• Caye A, Rocha TB, Anselmi L, et al. Attention-deficit/Hyperactivity disorder trajectories from childhood to young adulthood: evidence from a birth cohort supporting a late-onset syndrome. JAMA Psychiatry. 2016 Jul 1;73(7):705–712. PubMed PMID: 27192050.
   PubMed Web of Science ®Google Scholar
• Agnew-Blais JC, Polanczyk GV, Danese A, et al. Evaluation of the persistence, remission, and emergence of attention-deficit/hyperactivity disorder in young adulthood. JAMA Psychiatry. 2016 Jul 1;73(7):713–720. PubMed PMID: 27192174; PubMed Central PMCID: PMCPMC5475268.
   PubMed Web of Science ®Google Scholar
• Franke B, Michelini G, Asherson P, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol. 2018 Sep 5. PubMed PMID: 30195575. DOI:10.1016/j.euroneuro.2018.08.001
   Web of Science ®Google Scholar
• Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000 May;157(5):816–818. PubMed PMID: 10784477.
   PubMed Web of Science ®Google Scholar
• Larsson H, Lichtenstein P, Larsson JO. Genetic contributions to the development of ADHD subtypes from childhood to adolescence. J Am Acad Child Adolesc Psychiatry. 2006 Aug;45(8):973–981. PubMed PMID: 16865040.
   PubMed Web of Science ®Google Scholar
• Skirrow C, Asherson P. Emotional lability, comorbidity and impairment in adults with attention-deficit hyperactivity disorder. J Affect Disord. 2013 May;147(1–3):80–86. PubMed PMID: 23218897.
   PubMed Web of Science ®Google Scholar
• Surman CB, Biederman J, Spencer T, et al. Understanding deficient emotional self-regulation in adults with attention deficit hyperactivity disorder: a controlled study. Atten Defic Hyperact Disord. 2013 Sep;5(3):273–281. PubMed PMID: 23413201; PubMed Central PMCID: PMCPMC4009378.
   PubMedGoogle Scholar
• Weiss M, Murray C. Assessment and management of attention-deficit hyperactivity disorder in adults. CMAJ. 2003 Mar 18;168(6):715–722. PubMed PMID: 12642429; PubMed Central PMCID: PMCPMC154919.
   PubMed Web of Science ®Google Scholar
• Park S, Cho MJ, Chang SM, et al. Prevalence, correlates, and comorbidities of adult ADHD symptoms in Korea: results of the Korean epidemiologic catchment area study. Psychiatry Res. 2011 Apr 30;186(2–3):378–383. PubMed PMID: 20724004.
   PubMed Web of Science ®Google Scholar
• Pineiro-Dieguez B, Balanza-Martinez V, Garcia-Garcia P, et al. Psychiatric comorbidity at the time of diagnosis in adults with ADHD: the CAT study. J Atten Disord. 2016 Dec;20(12):1066–1075. PubMed PMID: 24464326.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 2006 Apr;163(4):716–723. PubMed PMID: 16585449; PubMed Central PMCID: PMCPMC2859678.
   PubMed Web of Science ®Google Scholar
• Simon N, Rolland B, Karila L. Methylphenidate in adults with attention deficit hyperactivity disorder and substance use disorders. Curr Pharm Des. 2015;21(23): 3359–3366. PubMed PMID: 26088112.
   PubMed Web of Science ®Google Scholar
• Wilens TE, Martelon M, Joshi G, et al. Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. J Am Acad Child Adolesc Psychiatry. 2011 Jun;50(6):543–553. PubMed PMID: 21621138; PubMed Central PMCID: PMCPMC3104208.
   PubMed Web of Science ®Google Scholar
• Horner BR, Scheibe KE. Prevalence and implications of attention-deficit hyperactivity disorder among adolescents in treatment for substance abuse. J Am Acad Child Adolesc Psychiatry. 1997 Jan;36(1):30–36. PubMed PMID: 9000778.
   PubMed Web of Science ®Google Scholar
• Arias AJ, Gelernter J, Chan G, et al. Correlates of co-occurring ADHD in drug-dependent subjects: prevalence and features of substance dependence and psychiatric disorders. Addict Behav. 2008 Sep;33(9):1199–1207. PubMed PMID: 18558465; PubMed Central PMCID: PMCPMC2532519.
   PubMed Web of Science ®Google Scholar
• Kooij JJ, Rosler M, Philipsen A, et al. Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial. BMC Psychiatry. 2013 Jan 24;13:36. PubMed PMID: 23347693; PubMed Central PMCID: PMCPMC3577504.
   PubMed Web of Science ®Google Scholar
• Martinez-Raga J, Szerman N, Knecht C, et al. Attention deficit hyperactivity disorder and dual disorders. Educational needs for an underdiagnosed condition. Int J Adolesc Med Health. 2013;25(3):231–243. PubMed PMID: 23846135.
   PubMedGoogle Scholar
• Charach A, Yeung E, Climans T, et al. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry. 2011 Jan;50(1):9–21. PubMed PMID: 21156266.
   PubMed Web of Science ®Google Scholar
• Lee SS, Humphreys KL, Flory K, et al. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011 Apr;31(3):328–341. PubMed PMID: 21382538; PubMed Central PMCID: PMCPMC3180912.
   PubMed Web of Science ®Google Scholar
• Brook DW, Brook JS, Zhang C, et al. Association between attention-deficit/hyperactivity disorder in adolescence and substance use disorders in adulthood. Arch Pediatr Adolesc Med. 2010 Oct;164(10):930–934. PubMed PMID: 20921350; PubMed Central PMCID: PMCPMC2951631.
   PubMed Web of Science ®Google Scholar
• Young JT, Carruthers S, Kaye S, et al. Comorbid attention deficit hyperactivity disorder and substance use disorder complexity and chronicity in treatment-seeking adults. Drug Alcohol Rev. 2015 Nov;34(6):683–693. PubMed PMID: 25790353.
   PubMed Web of Science ®Google Scholar
• Klassen LJ, Bilkey TS, Katzman MA, et al. Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations. Curr Drug Abuse Rev. 2012 Sep;5(3):190–198. PubMed PMID: 22571450.
   PubMedGoogle Scholar
• Volkow ND, Baler RD. NOW vs LATER brain circuits: implications for obesity and addiction. Trends Neurosci. 2015 Jun;38(6):345–352. PubMed PMID: 25959611
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, et al. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410–1415. PubMed PMID: 15950015.
   PubMed Web of Science ®Google Scholar
• Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005 Aug;162(8):1403–1413. PubMed PMID: 16055761.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Tomasi D, Wang GJ, et al. Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers. Mol Psychiatry. 2014 Sep;19(9):1037–1043. PubMed PMID: 24912491; PubMed Central PMCID: PMCPMC4827430.
   PubMed Web of Science ®Google Scholar
• Fowler JS, Volkow ND, Logan J, et al. Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine. Neuroimage. 2008 Dec;43(4):756–763. PubMed PMID: 18708148; PubMed Central PMCID: PMCPMC2606665.
   PubMed Web of Science ®Google Scholar
• Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet. 1999 Dec 18- 25;354(9196):2132–2133. PubMed PMID: 10609822.
   PubMed Web of Science ®Google Scholar
• Wilens TE, Adamson J, Sgambati S, et al. Do individuals with ADHD self-medicate with cigarettes and substances of abuse? Results from a controlled family study of ADHD. Am J Addict. 2007;16 Suppl 1:14–21; quiz 22–3. PubMed PMID: 17453603.
   Web of Science ®Google Scholar
• Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry. 1999 May;38(5):503–512. PubMed PMID: 10230181.
   PubMed Web of Science ®Google Scholar
• Katusic SK, Barbaresi WJ, Colligan RC, et al. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol. 2005 Oct;15(5):764–776. PubMed PMID: 16262593.
   PubMed Web of Science ®Google Scholar
• Groenman AP, Oosterlaan J, Rommelse NN, et al. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. Br J Psychiatry. 2013 Aug;203(2):112–119. PubMed PMID: 23846996.
   PubMed Web of Science ®Google Scholar
• Wilens TE, Adamson J, Monuteaux MC, et al. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med. 2008 Oct;162(10):916–921. PubMed PMID: 18838643; PubMed Central PMCID: PMCPMC2760975.
   PubMed Web of Science ®Google Scholar
• McCabe SE, Dickinson K, West BT, et al. Age of onset, duration, and type of medication therapy for attention-deficit/hyperactivity disorder and substance use during adolescence: a multi-cohort national study. J Am Acad Child Adolesc Psychiatry. 2016 Jun;55(6):479–486. PubMed PMID: 27238066; PubMed Central PMCID: PMCPMC4921895.
   PubMed Web of Science ®Google Scholar
• Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics. 1999 Aug;104(2):e20. PubMed PMID: 10429138.
   PubMed Web of Science ®Google Scholar
• Mannuzza S, Klein RG, Truong NL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry. 2008 May;165(5):604–609. PubMed PMID: 18381904; PubMed Central PMCID: PMCPMC2967384.
   PubMed Web of Science ®Google Scholar
• Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010 Jun;71(6):754–763. PubMed PMID: 20051220
   PubMed Web of Science ®Google Scholar
• Levin FR, Evans SM, Brooks DJ, et al. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend. 2006 Feb 1;81(2):137–148. PubMed PMID: 16102908.
   PubMed Web of Science ®Google Scholar
• Levin FR, Evans SM, Brooks DJ, et al. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 2007 Feb 23;87(1):20–29. PubMed PMID: 16930863.
   PubMed Web of Science ®Google Scholar
• Riggs PD, Hall SK, Mikulich-Gilbertson SK, et al. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry. 2004 Apr;43(4):420–429. PubMed PMID: 15187802.
   PubMed Web of Science ®Google Scholar
• Szobot CM, Rohde LA, Katz B, et al. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. Braz J Med Biol Res. 2008 Mar;41(3):250–257. PubMed PMID: 18327433.
   PubMed Web of Science ®Google Scholar
• Riggs PD, Winhusen T, Davies RD, et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry. 2011 Sep;50(9):903–914. PubMed PMID: 21871372; PubMed Central PMCID: PMCPMC3164797.
   PubMed Web of Science ®Google Scholar
• Konstenius M, Jayaram-Lindstrom N, Guterstam J, et al. Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction. 2014 Mar;109(3):440–449. PubMed PMID: 24118269; PubMed Central PMCID: PMCPMC4226329.
   PubMed Web of Science ®Google Scholar
• Levin FR, Mariani JJ, Specker S, et al. Extended-release mixed amphetamine salts Vs placebo for comorbid adult attention-deficit/Hyperactivity disorder and cocaine use disorder: a randomized clinical trial. JAMA Psychiatry. 2015 Jun;72(6):593–602. PubMed PMID: 25887096; PubMed Central PMCID: PMCPMC4456227.
   PubMed Web of Science ®Google Scholar
• Cunill R, Castells X, Tobias A, et al. Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. J Psychopharmacol. 2015 Jan;29(1):15–23. PubMed PMID: 25142405.
   PubMed Web of Science ®Google Scholar
• Perez-Mana C, Castells X, Torrens M, et al. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database Syst Rev. 2013 Sep 2;9:CD009695. PubMed PMID: 23996457.
   Google Scholar
• Dursteler-MacFarland KM, Farronato NS, Strasser J, et al. A randomized, controlled, pilot trial of methylphenidate and cognitive-behavioral group therapy for cocaine dependence in heroin prescription. J Clin Psychopharmacol. 2013 Feb;33(1):104–108. PubMed PMID: 23277248.
   PubMed Web of Science ®Google Scholar
• Collins SL, Levin FR, Foltin RW, et al. Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug Alcohol Depend. 2006 Apr 28;82(2):158–167. PubMed PMID: 16213109.
   PubMed Web of Science ®Google Scholar
• Konstenius M, Jayaram-Lindstrom N, Beck O, et al. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend. 2010 Apr 1;108(1–2):130–133. PubMed PMID: 20015599.
   PubMed Web of Science ®Google Scholar
• Thurstone C, Riggs PD, Salomonsen-Sautel S, et al. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. J Am Acad Child Adolesc Psychiatry. 2010 Jun;49(6):573–582. PubMed PMID: 20494267; PubMed Central PMCID: PMCPMC2876346.
   PubMed Web of Science ®Google Scholar
• Levin FR, Evans SM, McDowell DM, et al. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J Addict Dis. 2002;21(2):1–16. PubMed PMID: 11916368.
   PubMed Web of Science ®Google Scholar
• Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs. 2011 Feb;25(2):157–169. PubMed PMID: 21254791.
   PubMed Web of Science ®Google Scholar
• Skoglund C, Brandt L, D’Onofrio B, et al. Methylphenidate doses in attention deficit/hyperactivity disorder and comorbid substance use disorders. Eur Neuropsychopharmacol. 2017 Nov;27(11):1144–1152. PubMed PMID: 28935267.
   PubMed Web of Science ®Google Scholar
• Carmack SA, Block CL, Howell KK, et al. Methylphenidate enhances acquisition and retention of spatial memory. Neurosci Lett. 2014 May 1;567:45–50.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Tomasi D, et al. Methylphenidate attenuates limbic brain inhibition after cocaine-cues exposure in cocaine abusers. PLoS One. 2010 Jul 9;5(7):e11509. PubMed PMID: 20634975; PubMed Central PMCID: PMCPMC2901385.
   PubMed Web of Science ®Google Scholar
• Blix O, Dalteg A, Nilsson P. Treatment of opioid dependence and ADHD/ADD with opioid maintenance and central stimulants. Heroin Addict Relat Clin Probl. 2009;11(1):5–14.
   Web of Science ®Google Scholar
• Abel KF, Bramness JG, Martinsen EW. Stimulant medication for ADHD in opioid maintenance treatment. PubMed PMID: 25392060 J Dual Diagn. 2014;101:32–38.
   PubMed Web of Science ®Google Scholar
• McRae-Clark AL, Carter RE, Killeen TK, et al. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict. 2010 Nov-Dec;19(6):481–489. PubMed PMID: 20958842; PubMed Central PMCID: PMCPMC3019094.
   PubMed Web of Science ®Google Scholar
• Notzon DP, Mariani JJ, Pavlicova M, et al. Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence. Am J Addict. 2016 Dec;25(8):666–672. PubMed PMID: 28051838; PubMed Central PMCID: PMCPMC5435118.
   PubMed Web of Science ®Google Scholar
• Aharonovich E, Garawi F, Bisaga A, et al. Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence: effects on outcome. Am J Drug Alcohol Abuse. 2006;32(4):629–635. PubMed PMID: 17127551.
   PubMed Web of Science ®Google Scholar
• Cooper RE, Williams E, Seegobin S, et al. Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial. Eur Neuropsychopharmacol. 2017 Aug;27(8):795–808. PubMed PMID: 28576350.
   PubMed Web of Science ®Google Scholar
• Dalsgaard S, Mortensen PB, Frydenberg M, et al. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study. Addict Behav. 2014 Jan;39(1):325–328. PubMed PMID: 24090624.
   PubMed Web of Science ®Google Scholar
• Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008 Jul 1;96(1–2):145–154. PubMed PMID: 18403134.
   PubMed Web of Science ®Google Scholar
• Hammerness P, Petty C, Faraone SV, et al. Do stimulants reduce the risk for alcohol and substance use in youth with ADHD? A secondary analysis of a prospective, 24-month open-label study of osmotic-release methylphenidate. J Atten Disord. 2017 Jan;21(1):71–77. PubMed PMID: 23264367.
   PubMed Web of Science ®Google Scholar
• Mariani JJ, Levin FR. Treatment strategies for co-occurring ADHD and substance use disorders. Am J Addict. 2007;16 Suppl 1:45–54; quiz 55–6. PubMed PMID: 17453606; PubMed Central PMCID: PMCPMC2676785.
   PubMed Web of Science ®Google Scholar
• De Crescenzo F, Cortese S, Adamo N, et al. Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review. Evid Based Ment Health. 2017 Feb;20(1):4–11. PubMed PMID: 27993933.
   PubMed Web of Science ®Google Scholar
• Crunelle CL, van Den Brink W, Veltman DJ, et al. Low dopamine transporter occupancy by methylphenidate as a possible reason for reduced treatment effectiveness in ADHD patients with cocaine dependence. Eur Neuropsychopharmacol. 2013 Dec;23(12):1714–1723. PubMed PMID: 23731497.
   PubMed Web of Science ®Google Scholar
• Crits-Christoph P, Newberg A, Wintering N, et al. Dopamine transporter levels in cocaine dependent subjects. Drug Alcohol Depend. 2008 Nov 1;98(1–2):70–76. PubMed PMID: 18565692; PubMed Central PMCID: PMCPMC2564619.
   PubMed Web of Science ®Google Scholar
• Bidwell LC, Henry EA, Willcutt EG, et al. Childhood and current ADHD symptom dimensions are associated with more severe cannabis outcomes in college students. Drug Alcohol Depend. 2014 Feb 1;135:88–94. PubMed PMID: 24332802; PubMed Central PMCID: PMCPMC3904106.
   PubMed Web of Science ®Google Scholar
• Elkins IJ, Saunders GRB, Malone SM, et al. Associations between childhood ADHD, gender, and adolescent alcohol and marijuana involvement: a causally informative design. Drug Alcohol Depend. 2018 Mar 1;184:33–41. PubMed PMID: 29402677; PubMed Central PMCID: PMCPMC5818293.
   PubMed Web of Science ®Google Scholar
• Steinhausen HC, Bisgaard C. Substance use disorders in association with attention-deficit/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample. Eur Neuropsychopharmacol. 2014 Feb;24(2):232–241. PubMed PMID: 24314850.
   PubMed Web of Science ®Google Scholar
• Wilens TE. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am. 2004 Jun;27(2):283–301. PubMed PMID: 15063998.
   PubMed Web of Science ®Google Scholar
• Ling W, Chang L, Hillhouse M, et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction. 2014 Sep;109(9):1489–1500. PubMed PMID: 24825486; PubMed Central PMCID: PMCPMC4127124.
   PubMed Web of Science ®Google Scholar
• Buch S, Yao H, Guo M, et al. Cocaine and HIV-1 interplay: molecular mechanisms of action and addiction. J Neuroimmune Pharmacol. 2011 Dec;6(4):503–515. PubMed PMID: 21766222; PubMed Central PMCID: PMCPMC3208732.
   PubMed Web of Science ®Google Scholar
• Sharma HS, Muresanu D, Sharma A, et al. Cocaine-induced breakdown of the blood-brain barrier and neurotoxicity. Int Rev Neurobiol. 2009;88:297–334. PubMed PMID: 19897082.
   PubMed Web of Science ®Google Scholar
• Goldstein RZ, Volkow ND. Oral methylphenidate normalizes cingulate activity and decreases impulsivity in cocaine addiction during an emotionally salient cognitive task. Neuropsychopharmacology. 2011 Jan;36(1):366–367. PubMed PMID: 21116260; PubMed Central PMCID: PMCPMC3055523.
   PubMed Web of Science ®Google Scholar
• Li CS, Morgan PT, Matuskey D, et al. Biological markers of the effects of intravenous methylphenidate on improving inhibitory control in cocaine-dependent patients. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14455–14459. PubMed PMID: 20660731; PubMed Central PMCID: PMCPMC2922598.
   PubMed Web of Science ®Google Scholar
• Simmler LD, Wandeler R, Liechti ME. Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence. BMC Res Notes. 2013 Jun 5;6:220.
   PubMedGoogle Scholar
• Maremmani I, Agi M, Rugani F, et al. Clinical presentations of substance abuse in bipolar heroin addicts at time of treatment entry. Ann Gen Psychiatry. 2012 Sep 3;11(1):23. PubMed PMID: 22943591; PubMed Central PMCID: PMC3473306. eng.
   PubMedGoogle Scholar
• Maremmani AGI, Pacini M, Pani PP, et al. Possible trajectories of addictions: the role of bipolar spectrum. Heroin Addict Relat Clin Probl. 2016;18(4):23–32.
   Web of Science ®Google Scholar
• Maremmani I, Pacini M, Perugi G, et al. Cocaine abuse and the bipolar spectrum in 1090 heroin addicts: clinical observations and a proposed pathophysiologic model. J Affect Disord. 2008 Feb;106(1–2):55–61. PubMed PMID: 17669508; eng.
   PubMed Web of Science ®Google Scholar
• Pacini M, Maremmani AGI, Ceccanti M, et al. Former heroin-dependent alcohol use disorder patients. Prevalence, addiction history and clinical features. Alcohol Alcohol. 2015 Mar 31; PubMed PMID: 25827777; Eng. DOI:10.1093/alcalc/agv028
   PubMed Web of Science ®Google Scholar
• Maremmani I. The principles and practice of methadone treatment. Pisa: Pacini Editore Medicina & AU-CNS; 2009.
   Google Scholar
• Pacini M, Maremmani AGI, Rovai L, et al. Treating heroin addicts. Blocking dosages and stimulation-stabilization of opioidergic system [Expert opinion]. Heroin Addict Relat Clin Probl. 2010;12(4):41–48. UK.
   Web of Science ®Google Scholar
• Maremmani I, Pacini M, Lubrano S, et al. When ‘enough’ is still not ‘enough’. Effectiveness of high-dose methadone in the treatment of heroin addiction. Heroin Addict Relat Clin Probl. 2003;5(1):17–32.
   Google Scholar
• Brady TM, Salvucci S, Sverdlov LS, et al. Methadone dosage and retention: an examination of the 60 mg/day threshold [Comparative Study]. J Addict Dis. 2005;24(3):23–47. PubMed PMID: 16186081; eng.
   PubMed Web of Science ®Google Scholar
• Maremmani I, Shinderman MS. Alcohol, benzodiazepines and other drugs use in heroin addicts treated with methadone. Polyabuse or undermedication? [Proposals]. Heroin Addict Relat Clin Probl. 1999;1(2): 7–13. UK.
   Google Scholar
• Lubrano S, Pacini M, Giuntoli G, et al. Is craving for heroin and alcohol related to low methadone dosages in methadone maintened patients [research report]. Heroin Addict Relat Clin Probl. 2002;4(2):11–17. UK.
   Google Scholar
• Maremmani AG, Rovai L, Bacciardi S, et al. The long-term outcomes of heroin dependent-treatment-resistant patients with bipolar 1 comorbidity after admission to enhanced methadone maintenance [research support, non-U.S. Gov’t]. J Affect Disord. 2013 Nov;151(2):582–589. PubMed PMID: 23931828; eng.
   PubMed Web of Science ®Google Scholar
• Maremmani I, Zolesi O, Aglietti M, et al. Methadone dose and retention during treatment of heroin addicts with axis I psychiatric comorbidity. J Addict Dis. 2000;19(2):29–41. PubMed PMID: 10809518; eng.
   PubMed Web of Science ®Google Scholar
• Maremmani I, Pacini M, Canoniero S, et al. Dose determination in dual diagnosed heroin addicts during methadone treatment. Heroin Addict Relat Clin Probl. 2010;12(1):17–24. UK.
   Web of Science ®Google Scholar
• Peles E, Kreek MJ, Kellogg S, et al. High methadone dose significantly reduces cocaine use in methadone maintenance treatment (MMT) patients [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. J Addict Dis. 2006;25(1):43–50. PubMed PMID: 16597572; eng.
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime. World Drug Report. 2013.
   Google Scholar
• Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev. 2008 1 PubMed PMID: 19630708;Jan(1):81–98.
   Google Scholar
• Gruber AJ, Pope HG, Hudson JI, et al. Attributes of long-term heavy cannabis users: a case-control study. Psychol Med. 2003 Nov;33(8):1415–1422. PubMed PMID: 14672250.
   PubMed Web of Science ®Google Scholar
• Buckner RL, Andrews-Hanna JR, Schacter DL. The brain’s default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008 Mar;1124:1–38. PubMed PMID: 18400922.
   PubMed Web of Science ®Google Scholar
• Raichle ME, MacLeod AM, Snyder AZ, et al. A default mode of brain function. Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):676–682. PubMed PMID: 11209064; PubMed Central PMCID: PMCPMC14647.
   PubMed Web of Science ®Google Scholar
• Whitfield-Gabrieli S, Ford JM. Default mode network activity and connectivity in psychopathology. Annu Rev Clin Psychol. 2012;8:49–76. PubMed PMID: 22224834.
   PubMed Web of Science ®Google Scholar
• Metin B, Krebs RM, Wiersema JR, et al. Dysfunctional modulation of default mode network activity in attention-deficit/hyperactivity disorder. J Abnorm Psychol. 2015 Feb;124(1):208–214. PubMed PMID: 25314265.
   PubMed Web of Science ®Google Scholar
• van Hell HH, Jager G, Bossong MG, et al. Involvement of the endocannabinoid system in reward processing in the human brain. Psychopharmacology (Berl). 2012 Feb;219(4):981–990. PubMed PMID: 21822593; PubMed Central PMCID: PMCPMC3266503.
   PubMed Web of Science ®Google Scholar
• Chauchard E, Hartwell KJ, McRae-Clark AL, et al. Cannabis withdrawal in adults with attention-deficit/hyperactivity disorder. Prim Care Companion CNS Disord. 2018 Feb 22;20(1). PubMed PMID: 29489073.
   PubMedGoogle Scholar
• Wiers CE, Shokri-Kojori E, Wong CT, et al. Cannabis abusers show hypofrontality and blunted brain responses to a stimulant challenge in females but not in males. Neuropsychopharmacology. 2016 Sep;41(10):2596–2605. PubMed PMID: 27156854; PubMed Central PMCID: PMCPMC4987858.
   PubMed Web of Science ®Google Scholar
• Howard AL, Molina BS, Swanson JM, et al. Developmental progression to early adult binge drinking and marijuana use from worsening versus stable trajectories of adolescent attention deficit/hyperactivity disorder and delinquency. Addiction. 2015 May;110(5):784–795. PubMed PMID: 25664657; PubMed Central PMCID: PMCPMC4398637.
   PubMed Web of Science ®Google Scholar
• Tamm L, Epstein JN, Lisdahl KM, et al. Impact of ADHD and cannabis use on executive functioning in young adults. Drug Alcohol Depend. 2013 Dec 1;133(2):607–614. PubMed PMID: 23992650; PubMed Central PMCID: PMCPMC3820098.
   PubMed Web of Science ®Google Scholar
• Brinkman WB, Epstein JN, Auinger P, et al. Association of attention-deficit/hyperactivity disorder and conduct disorder with early tobacco and alcohol use. Drug Alcohol Depend. 2015 Feb 1;147:183–189. PubMed PMID: 25487225; PubMed Central PMCID: PMCPMC4297712.
   PubMed Web of Science ®Google Scholar
• Molina BS, Pelham WE, Gnagy EM, et al. Attention-deficit/hyperactivity disorder risk for heavy drinking and alcohol use disorder is age specific. Alcohol Clin Exp Res. 2007 Apr;31(4):643–654. PubMed PMID: 17374044; PubMed Central PMCID: PMCPMC2680082.
   PubMed Web of Science ®Google Scholar
• Knop J, Penick EC, Nickel EJ, et al. Childhood ADHD and conduct disorder as independent predictors of male alcohol dependence at age 40. J Stud Alcohol Drugs. 2009 Mar;70(2):169–177. PubMed PMID: 19261228; PubMed Central PMCID: PMCPMC2653603.
   PubMed Web of Science ®Google Scholar
• van Emmerik-van Oortmerssen K, van de Glind G, van Den Brink W, et al. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend. 2012 Apr 1;122(1–2):11–19. PubMed PMID: 22209385.
   PubMed Web of Science ®Google Scholar
• Luderer M, Sick C, Kaplan-Wickel N, et al. Prevalence estimates of ADHD in a sample of inpatients with alcohol dependence. J Atten Disord. 2018 Jan 1. PubMed PMID: 29308693. DOI: 10.1177/1087054717750272
   PubMedGoogle Scholar
• Fergusson DM, Horwood LJ, Ridder EM. Conduct and attentional problems in childhood and adolescence and later substance use, abuse and dependence: results of a 25-year longitudinal study. Drug Alcohol Depend. 2007 Apr;88 Suppl 1:S14–S26. PubMed PMID: 17292565.
   PubMed Web of Science ®Google Scholar
• Bjork JM, Hommer DW, Grant SJ, et al. Impulsivity in abstinent alcohol-dependent patients: relation to control subjects and type 1-/type 2-like traits. Alcohol. 2004 Oct-Nov;34(2–3):133–150. PubMed PMID: 15902907.
   PubMed Web of Science ®Google Scholar
• Dom G, De Wilde B, Hulstijn W, et al. Behavioural aspects of impulsivity in alcoholics with and without a cluster-B personality disorder. Alcohol Alcohol. 2006 Jul–Aug;41(4):412–420. PubMed PMID: 16782972.
   PubMed Web of Science ®Google Scholar
• Soloff PH, Lynch KG, Moss HB. Serotonin, impulsivity, and alcohol use disorders in the older adolescent: a psychobiological study. Alcohol Clin Exp Res. 2000 Nov;24(11):1609–1619. PubMed PMID: 11104107.
   PubMed Web of Science ®Google Scholar
• Weafer J, Milich R, Fillmore MT. Behavioral components of impulsivity predict alcohol consumption in adults with ADHD and healthy controls. Drug Alcohol Depend. 2011 Jan 15;113(2–3):139–146. PubMed PMID: 20863628; PubMed Central PMCID: PMCPMC3010339.
   PubMed Web of Science ®Google Scholar
• Blume AW, Schmaling KB, Marlatt GA. Memory, executive cognitive function, and readiness to change drinking behavior. Addict Behav. 2005 Feb;30(2):301–314. PubMed PMID: 15621401.
   PubMed Web of Science ®Google Scholar
• Tarter RE, Kirisci L, Reynolds M, et al. Neurobehavior disinhibition in childhood predicts suicide potential and substance use disorder by young adulthood. Drug Alcohol Depend. 2004 Dec 7;76(Suppl):S45–S52. PubMed PMID: 15555816.
   PubMedGoogle Scholar
• Dupont RL, Coleman JJ, Bucher RH, et al. Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Am J Addict. 2008 May–Jun;17(3):167–171. PubMed PMID: 18463991.
   PubMed Web of Science ®Google Scholar
• Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry. 2010 Sep 3;10:67. PubMed PMID: 20815868; PubMed Central PMCID: PMCPMC2942810.
   PubMed Web of Science ®Google Scholar
• Winhusen TM, Somoza EC, Brigham GS, et al. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010 Dec;71(12):1680–1688. PubMed PMID: 20492837; PubMed Central PMCID: PMCPMC3151610.
   PubMed Web of Science ®Google Scholar
• Nunes EV, Covey LS, Brigham G, et al. Treating nicotine dependence by targeting attention-deficit/hyperactivity disorder (ADHD) with OROS methylphenidate: the role of baseline ADHD severity and treatment response. J Clin Psychiatry. 2013 Oct;74(10):983–990. PubMed PMID: 24229749; PubMed Central PMCID: PMCPMC3946795.
   PubMed Web of Science ®Google Scholar
• Gehricke JG, Hong N, Wigal TL, et al. ADHD medication reduces cotinine levels and withdrawal in smokers with ADHD. Pharmacol Biochem Behav. 2011 May;98(3):485–491. PubMed PMID: 21356232; PubMed Central PMCID: PMCPMC3065552.
   PubMed Web of Science ®Google Scholar
• Kollins SH, English JS, Itchon-Ramos N, et al. A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD. J Atten Disord. 2014 Feb;18(2):158–168. PubMed PMID: 22508760; PubMed Central PMCID: PMCPMC3421044.
   PubMed Web of Science ®Google Scholar
• Ray R, Rukstalis M, Jepson C, et al. Effects of atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence. J Psychopharmacol. 2009 Mar;23(2):168–176. PubMed PMID: 18515446.
   PubMed Web of Science ®Google Scholar